|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Matthew L. Albert, Head of Lab, Dendritic Cell Immunobiology, Director, Center for Human Immunology, Institut Pasteur
|
|
|
|
Alison Banham, Nuffield Department of Clinical Laboratory Sciences, Oxford University
|
|
|
|
Chris Chamberlain, Medical Director Personalised Medicine Astrazeneca
|
|
|
|
Dan Chelsky, Cheif Scientific Officer, Caprion Proteomics Inc.
|
|
|
|
Gary Coulton, Director, St. George's Medical Biomics Centre, St. George's University of London
|
|
|
|
Ratko Djukanovic, Professor in Respiratory Medicine, Director of the NHR Respiratory Biomedical Research Unit, Southampton Univeristy
|
|
|
|
Nicholas Dracopoli, Vice President, Centocor Research & Development
|
|
|
|
Jeff Evans, CRUK Professor of Translational Cancer Research, University of Glasgow
|
|
|
|
Aiden Flynn, Director Biomarkers and Analytics, GlaxoSmithKline
|
|
|
|
Neil French, Senior Scientific Operations Manager, MRC Centre for Drug Safety Science, Department of Pharmacology & Therapeutics, The University of Liverpool
|
|
|
|
Steve Furlong, Safety Science Lead, AstraZeneca Clinical Development
|
|
|
|
Craig Gelfand, Director, Advanced Technologies, Diagnostics - Preanalytical Systems, BD Diagnostics
|
|
|
|
Geoff Hale, Managing Director BioPharma Services Europe, Millipore
|
|
|
|
Brett Hall, Team Lead Biomarkers, Janssen Pharmaceutica (a division of J&J)
|
|
|
|
Thomas Herget, Senior Director, New Technology Evaluation, Division Chemicals R&D, Merck KGaA
|
|
|
|
Andrew Hughes, Worldwide Director Early Phase Oncology Clinical Development, Astrazeneca
|
|
|
|
Patricia Hurley, Head of Project Management and Biomarkers Division, ERA Consulting (UK) Ltd
|
|
|
|
Mark Jones, Associate Director Molecular Biomarkers, Global Exploratory Development, UCB New Medicines
|
|
|
|
Francis Kalush, Network Leader for the Diagnostics (In Vivo and In Vitro) and Personalized Medicine Network, FDA
|
|
|
|
Martina Kaufmann, Biomarker Project Leader, Head Oncology Biomarkers & Imaging, Novartis
|
|
|
|
Andreas Keller, Head of Genomic Services, Febit
|
|
|
|
Richard Kennedy, VP of Experimental Medicine, Almac Diagnositcs
|
|
|
|
Iain Kilty, Director Allergy & Respoiratoy Research Unit, Pfizer
|
|
|
|
Sabine Küsters, Director of Scientific Relations, Rules Based Medicine
|
|
|
|
Jennifer Larsen, Translational Medicine Scientist, Lundbeck
|
|
|
|
Mike Lau, Prinicipal Clinical Development Scientist, GSK Oncology
|
|
|
|
Mark Lindsay, Reader in Biopharmaceutics, Manchester University
|
|
|
|
Theo Luider, Head of the Laboratories of Neuro-Oncology, Department of Neurology, Erasmus, University of Rotterdam
|
|
|
|
Duncan McHale, Vice President, Medical Director Personalized Healthcare, Astrazeneca
|
|
|
|
Huseyin Mehmet, Director Exploratory Biomarkers, Diabetes, Merck Research Laboratories
|
|
|
|
Gino Miele, Associate Director, Head of Genomics, Wyeth
|
|
|
|
Samila Mihindukulasuriya, Senior Contract Analyst, Biomarkers, GSK
|
|
|
|
Sterghios Moschos, Prinicipal Scientist, Biotherapeutics, Pfizer
|
|
|
|
Samual Murray, President, Greek Society of Molecular Oncology, University of Ioannina Cancer Biobank
|
|
|
|
Valerie Nedbal, JMP Pharmaceutical Technical, Manager, SAS Institute France
|
|
|
|
Roger Palframan, Director of Cellular Sciences, UCB
|
|
|
|
Harsukh Parmar, Director, Global Discovery medicine, Respiratory & Inflammation Therapy Area, Astrazeneca
|
|
|
|
Maribeth Raines, Director, Scientific Affairs Valencia, California, USA, Quest Diagnostics
|
|
|
|
Simon Read, Leader Biomarker and Experimental Medicine, F. Hoffmann - La Roche
|
|
|
|
David Reynolds, Senior Director, Experimental Biological Sciences, Pfizer
|
|
|
|
Henry Rodriguez, Clinical Proteomic Technologies for Cancer, Office of the Director, National Cancer Institute
|
|
|
|
Sanja Selak, Head of Serology and Immune Assays Department, InterCell AG
|
|
|
|
Jonathan Sheldon, Director of Translational Medicine, IDBS
|
|
|
|
Matt Squires, Associate Director Translational Biology, Astex Therapeutics
|
|
|
|
Linda Surh, CEDD Global Regulatory Affairs, Neurosciences and Pharmacogenetics, GlaxoSmithKline
|
|
|
|
Miro Venturi, Senior Biomarker & Experimental Medicine Leader, Roche Pharma Development
|
|
|
|
Kristof Vercruysse, Associate Director Clinical Operations, Ablynx
|
|
|
|
Robert Wilkinson, Prinicpal Scientist, Cancer and Infection Research Area, Astrazeneca
|
|
|
|
Ian Wilson, Senior Principal Scientist, Department of Drug Metabolism and Pharmacokinetics, Astrazeneca
|
|
|
|
Christer Wingren, Assistant Professor, Department of Immunotechnology, Lund University, Sweden
|
|
|
|
Hans Winkler, Senior Director, Global Head Oncology Biomarkers, Ortho Biotech - Johnson & Johnson
|
|
|
|
|
|
|
|
Speakers
